Thai researchers advance vaccine development, aiming to provide inoculations to Southeast Asia

Henrietta Brewer
May 26, 2020

The WHO estimates there are more than 100 other vaccine candidates that are now in earlier stages of development, with smaller firms competing alongside larger drug producers like Pfizer Inc., AstraZeneca Plc., and academic institutions.

The Phase 1/2 clinical trial will be held in two parts.

The southern hemisphere's first human trial of a coronavirus vaccine is starting today in Australia, and the results could be ready in in just over a month.

Another vaccine progressing to more advanced clinical trials is called ChAdOx1 nCoV-19, which is being developed by scientists at Oxford University.

NEWS 1130 is working hard to get you the information you need about the COVID-19 pandemic.

There are now over 120 separate groups working to produce a COVID-19 vaccine.

Clinical research organisation Nucleus Network will run the early stages of testing and expand the trial to clinics in Brisbane within a week.

He believed New Zealand had the talent to develop a vaccine.

Roque also said President Rodrigo Duterte will review the recommendations of the DOST to establish the Virology Science and Technology Institute, and reactivate the Pharmaceutical Development Unit at the DOST-Industrial Technology Development Institute.

"If we didn't have enough data that really supported its safe use in humans, we wouldn't be doing this trial". In the tests completed so far, researchers have observed that a single dose of this vaccine produced certain immune cells known as T cells within two weeks and the antibodies required for immunity reached its peak within 28 days. It will be a random, observer-blind placebo-controlled trial that will evaluate the safety and immunogenicity of the vaccine.

Five monkeys will receive the vaccine in low doses, and five will receive the vaccine in higher doses. They include nausea, fatigue, pain, fever and headache. "Our higher price target reflects our continued confidence in the successful completion of development and global approval of NVX-CoV2373, with an increased estimate for the procurement of this vaccine in 2021, from 100M to 300M doses, at $10/dose, for a ~3% share of global vaccine consumption, with our continued assumption for a $5 CGS/dose" he explains. The intention is to generate an immune response and prep the body to fight back future infection.

"We injected the vaccine into 13 long-tailed macaques on Saturday".

"Because that certainly will make the whole Olympics and Paralympics much more viable, if we see global transmission rates coming under control over the next four to six months". Researchers have expressed that it has the potential to prevent COVID-19. At least five other vaccines are underway elsewhere, including three in China and two others in the United Kingdom and Russian Federation.

Other reports by iNewsToday